HighPoint Advisor Group LLC Lowers Position in Pfizer Inc. (NYSE:PFE)

HighPoint Advisor Group LLC lessened its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 5.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 202,341 shares of the biopharmaceutical company's stock after selling 10,819 shares during the quarter. HighPoint Advisor Group LLC's holdings in Pfizer were worth $5,183,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of PFE. United Bank boosted its stake in Pfizer by 3.7% during the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company's stock valued at $1,030,000 after purchasing an additional 1,277 shares during the last quarter. Fred Alger Management LLC lifted its holdings in shares of Pfizer by 7.4% during the third quarter. Fred Alger Management LLC now owns 102,668 shares of the biopharmaceutical company's stock valued at $2,971,000 after purchasing an additional 7,076 shares in the last quarter. Tradition Wealth Management LLC boosted its position in shares of Pfizer by 4.5% during the third quarter. Tradition Wealth Management LLC now owns 25,358 shares of the biopharmaceutical company's stock valued at $734,000 after buying an additional 1,099 shares during the last quarter. Bellevue Group AG increased its holdings in Pfizer by 59.2% in the 3rd quarter. Bellevue Group AG now owns 141,075 shares of the biopharmaceutical company's stock worth $4,083,000 after buying an additional 52,461 shares in the last quarter. Finally, Semmax Financial Advisors Inc. raised its position in Pfizer by 3.2% in the 3rd quarter. Semmax Financial Advisors Inc. now owns 101,267 shares of the biopharmaceutical company's stock worth $2,695,000 after buying an additional 3,185 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on PFE shares. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. UBS Group cut their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Bank of America reiterated a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $31.92.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.06% of the stock is currently owned by insiders.

Pfizer Stock Performance

Shares of NYSE PFE traded up $0.15 during trading on Monday, hitting $25.36. The company had a trading volume of 53,460,722 shares, compared to its average volume of 39,095,040. The stock has a 50 day simple moving average of $26.05 and a 200 day simple moving average of $26.88. The firm has a market capitalization of $143.80 billion, a P/E ratio of 17.98, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.10 earnings per share. As a group, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.